Saturday 17 October 2026
Export UPB’s income statement to Excel — free account
Upstream Bio, Inc.
Upstream Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue fell 17.5%, EPS grew 1.35% and free cash flow grew 9.33%, each against the same quarter a year earlier.
2.76
0.61
−18.10%
Follow UPB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (46.05%) | (41.83%) | (35.43%) | (112.50%) |
+7 more TTM periods Free account |
|
| (44.61%) | (40.50%) | (34.34%) | (39.36%) | ||
ROIC |
(1,100.93%) | (1,141.43%) | 0.00% | (1,426.34%) | |
Return on Tangible Assets |
(57.95%) | (51.72%) | (42.33%) | (32.50%) | |
Average Days of Receivables |
89.23 | 113.61 | 85.43 | 89.07 | |
Free Cash Flow per Share |
(2.50) | (2.58) | (2.48) | (2.28) | |
Free Cash Flow |
(136.34) | (139.96) | (133.62) | (122.88) | |
Capital Expenditures |
— | — | (0.35) | (0.62) | |
| Other line items | |||||
Cash ROIC |
(25.62%) | (23.38%) | (19.61%) | (16.36%) | |
Accounts Receivable Turnover |
3.70 | 4.15 | 4.46 | 4.34 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,616.78% | 4,442.32% | 4,793.48% | 4,230.44% | |
Selling, General and Administrative Expense of Revenue |
865.86% | 834.17% | 925.33% | 889.64% | |
Share Based Compensation of Revenue |
446.52% | 371.58% | 362.02% | 354.13% | |
Operating CF/Net income |
0.87 | 0.89 | 0.93 | 1.00 | |
Depreciation/Fixed assets |
1.36 | (0.64) | (2.35) | (3.27) | |
Capex/Depreciation |
0.00 | 0.00 | 0.27 | 0.31 | |
Revenue per Share |
0.06 | 0.06 | 0.05 | 0.05 | |
Operating CF per Share |
(2.50) | (2.58) | (2.47) | (2.27) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.12 | 0.22 |
Columns are period end dates